Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The Efficacy and Safety of Intra-Arterial Administration of REX-001 to Treat Ischaemic Ulcers in Subjects with Critical Limb Ischaemia Rutherford Category 5 and Diabetes Mellitus: A Pivotal, Placebo-Controlled, Double-Blind, Parallel-Group, Adaptive Trial

Trial Profile

The Efficacy and Safety of Intra-Arterial Administration of REX-001 to Treat Ischaemic Ulcers in Subjects with Critical Limb Ischaemia Rutherford Category 5 and Diabetes Mellitus: A Pivotal, Placebo-Controlled, Double-Blind, Parallel-Group, Adaptive Trial

Recruiting
Phase of Trial: Phase III

Latest Information Update: 27 Nov 2018

At a glance

  • Drugs Rexmyelocel T (Primary)
  • Indications Peripheral ischaemia
  • Focus Registrational; Therapeutic Use
  • Sponsors Rexgenero
  • Most Recent Events

    • 07 Sep 2018 Last checked against ClinicalTrials.gov record.
    • 28 Aug 2018 Planned End Date changed from 30 Dec 2019 to 31 Oct 2021.
    • 28 Aug 2018 Planned primary completion date changed from 30 Dec 2018 to 31 Oct 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top